Canada markets close in 5 hours 34 minutes

Heat Biologics, Inc. (HTBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.2062-0.0438 (-3.50%)
As of 10:26AM EDT. Market open.
Sign in to post a message.
  • D
    Dr. Moparjarian
    For several months now I have noticed very few people on this page are "Investors". Most are Used car Salesman! I personally own just over 20,000 shares of HTBX at a cost basis of $0.72. No complaints here!
  • m
    mark
    The upgrade by Justin Zelin with B. Riley is the biggest vote of confidence you can receive from a research firm. He comes to B. Riley packed with an impressive resume. He has covered over 45 companies for Canaccord Genuity, SVB Leerink and Oppenheimer & Co. Zelin is formally a trained scientist and has worked on immuno-oncology and infectious desease therapeutic development. He also holds a Masters degree in Biotechnology and graduated with honors at Harvard.

    He has done a deep dive into Heats pipeline and he was hired for the sole purpose of finding diamonds for investors. This is not a one shot on goal company and should Heat Biologics find the key to being a part of the solution for a Covid Vaccine this stock will fly!! Added again today at 1.30 and will continue to add until this company leaves the launch pad!

    Long and strong 🔥 Heat !!!
  • A
    ARC
    B. Riley Securities initiates HTBX with a Buy and price target of $4. Analyst Justin Zelin said, "Heat has shown a promising ability to activate and stimulate T-cell responses, an important foundation of effective vaccines for cancer and infectious diseases, including SARS-CoV-2. Distinguished from the pack, Heat is not a typical neoantigen-based vaccine company; it focuses on an allogeneic "off-the-shelf" cell-based vaccine approach, which relies on the robust effects of the cellular heat shock protein (HSP) glycoprotein (gp) 96, the immune system's "Swiss army knife." Heat and other's gp96-based vaccines have been shown to induce potent and specific T-cell responses. We view Heat's Tcell activation data as an important differentiating factor and are seeing a growing appreciation for T-cell immunity in the field, as well. We believe HTBX has an attractive valuation relative to other vaccine companies with SARS-CoV-2 candidates and a promising allogeneic cancer vaccine poised to enter pivotal Phase III clinical development. We view HTBX as a value vaccine play aiming to heat up the immuno-oncology and SARS-CoV-2 vaccine landscapes, with elusive T-cell activation data that is notably lacking in front-runner SARS-CoV-2 vaccine data presentations."
  • I
    IVO
    Goodmorning, specially to Wayne, market is set to go green after the first trading hour.
  • T
    Theo
    I get tired of this stock and i put a part of my position to get back some of my looses in wter a small cbd player that will benefit from biden win as others cannabis stocks. I don’t sell all my stocks cos I believe htbx will hit 5$ but I don’t know when.
  • P
    Paul
    T-cells will definitely contribute to mitigation of covid virus. Awaiting news of ongoing due diligence by well recognized concerns.
  • M
    Moonshiner
    Good Morning!
  • K
    Kirtz
    This is it guys, when people here are angry and frustrated the stock will jump to $13 for a day like the KXIN stock, they all got angry to the point of selling last Friday then this Monday shoots up.
  • J
    Just a human !
    SHOW ME another Cancer stock with Phase 3 trials, $100 million cash and a potential Covid vaccine, Buyout /Partnership is a strong possibility
  • C
    Carolyn
    Not selling, just not liking the back & forth add a penny, take a penny action. This is without a doubt, the most boring/exciting stock I hold! Momma told me there would be days like these...
  • f
    flipflop
    All eyes on a hurdle race for a SARS-CoV-2 vaccine
    Leading COVID-19 vaccine candidates have progressed through laboratory tests at record speed. Two early clinical trials suggest that immunization delivers a favourable immune response and safety profile, but questions remain.
    he secondary goal of these early-stage clinical trials is to assess immunogenicity — the ability of a vaccine to stimulate a detectable immune response to the vaccine target (Fig. 1). This typically involves assessing components of what is known as the adaptive branch of the immune system. The features of interest are vaccine-specific antibody responses and immune cells called CD4 (or helper) T cells and CD8 (cytotoxic) T cells. These T cells can directly target cells infected with the virus, or collaborate with antibody-producing B cells. The best vaccines elicit long-lasting responses that produce ‘neutralizing’ antibodies, which act to hinder or prevent an infectious agent from causing illness5. Once phase I and II trials have been completed, a phase III study can be conducted to determine whether the vaccine affects how susceptible people are to a disease.

    https://www.nature.com/articles/d41586-020-02926-w
  • J
    JamesP
    Hello all - 1st post here - have a good sized long position now as I recently quadrupled my share count over the past week. Looking forward to today's analyst $4 price target becoming a reality.
  • f
    flipflop
    Lucas and colleagues performed extensive analyses of immune responses over time (longitudinal studies) in 113 people hospitalized with COVID-19 who had moderate or severe disease, and assessed a similar number of SARS-CoV-2-free healthy people as controls. The authors analysed molecules in blood plasma (Fig. 1) and monitored peripheral blood mononuclear cells — white blood cells of the immune system such as CD4 T cells, CD8 T cells and B cells. The longitudinal nature of this study enables conclusions to be drawn that wouldn’t be possible from analysing cross-sectional studies that don’t follow individuals over time
    https://www.nature.com/articles/d41586-020-02379-1
  • C
    Carolyn
    it's a good tweet,,,
    "Our gp96 platform, which is designed to drive T-cells to fight #COVID19 and more, has been dosed in over 300 patients in several Heat-sponsored oncology trials, with a positive safety profile thus far in the clinic."
  • s
    sweetcheeks
    The best case scenario would be to couple Heat’s vaccine with one of the big pharma candidates. This would give the patient the antibodies to fight off the current Covid-19 infection and the T-cells for long term immunity. This would be a better approach, because antibodies fade and patient can be reinfected if they don’t have the T-cells.
  • M
    Moonshiner
    Good Morning!!!
  • C
    Carolyn
    I think once the Asia Vaccine conference is over, we should see good upside movement. Remember a lot of big players are at that conference and Jeff is a keynote speaker.
  • T
    T
    the artificial walls are down this morning on level 2. Very rare for this stock. Almost always MM with the big walls. Guess they are finally going to let it move
  • M
    Mohamed
    Good morning LONGS .. B.RILEY starts a BUY of HTBX at $4.00 few minutes ago !! Volume very impressive early morning !! Fidelity $2.98 public sentiment Extra Positive